JP2021510153A - 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 - Google Patents

膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 Download PDF

Info

Publication number
JP2021510153A
JP2021510153A JP2020537237A JP2020537237A JP2021510153A JP 2021510153 A JP2021510153 A JP 2021510153A JP 2020537237 A JP2020537237 A JP 2020537237A JP 2020537237 A JP2020537237 A JP 2020537237A JP 2021510153 A JP2021510153 A JP 2021510153A
Authority
JP
Japan
Prior art keywords
diabetes
dyrk1a
subject
human
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020537237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510153A5 (cg-RX-API-DMAC10.html
Inventor
アンドリュー エフ. スチュアート
アンドリュー エフ. スチュアート
コートニー アケイフィ
コートニー アケイフィ
ペン ワン
ペン ワン
ボブ デヴィータ
ボブ デヴィータ
Original Assignee
アイカーン スクール オブ メディシン アット マウント サイナイ
アイカーン スクール オブ メディシン アット マウント サイナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディシン アット マウント サイナイ, アイカーン スクール オブ メディシン アット マウント サイナイ filed Critical アイカーン スクール オブ メディシン アット マウント サイナイ
Publication of JP2021510153A publication Critical patent/JP2021510153A/ja
Publication of JP2021510153A5 publication Critical patent/JP2021510153A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020537237A 2018-01-05 2019-01-05 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 Pending JP2021510153A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614136P 2018-01-05 2018-01-05
US62/614,136 2018-01-05
PCT/US2019/012442 WO2019136320A1 (en) 2018-01-05 2019-01-05 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition

Publications (2)

Publication Number Publication Date
JP2021510153A true JP2021510153A (ja) 2021-04-15
JP2021510153A5 JP2021510153A5 (cg-RX-API-DMAC10.html) 2022-01-13

Family

ID=67143990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020537237A Pending JP2021510153A (ja) 2018-01-05 2019-01-05 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物

Country Status (7)

Country Link
US (2) US11788064B2 (cg-RX-API-DMAC10.html)
EP (1) EP3735419A4 (cg-RX-API-DMAC10.html)
JP (1) JP2021510153A (cg-RX-API-DMAC10.html)
CN (1) CN111819193A (cg-RX-API-DMAC10.html)
AU (1) AU2019205944A1 (cg-RX-API-DMAC10.html)
CA (1) CA3086925A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019136320A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
WO2021114314A1 (en) 2019-12-14 2021-06-17 Tongji University Novel heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases
WO2021114315A1 (en) 2019-12-14 2021-06-17 Shanghai East Hospital Use of heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases
WO2022166458A1 (zh) * 2021-02-05 2022-08-11 浙江仙琚萃泽医药科技有限公司 一种可吸入的药物粉末制剂及其制备方法
EP4532689A4 (en) * 2022-06-01 2026-05-27 Icahn School Med Mount Sinai Polytherapy with immunomodulators, DYRK1A inhibitors, and GLP1R agonists for the treatment of type 1 diabetes
WO2024008614A1 (en) * 2022-07-08 2024-01-11 Société des Produits Nestlé S.A. Use of 25-hydroxycholesterol for diabetic treatment and/or prevention
WO2026008066A1 (en) * 2024-07-05 2026-01-08 Shanghai Vitalgen Biopharma Co., Ltd. Targeting prkar2b to enhance beta-islet function and survival for treatments of diabetes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013514781A (ja) * 2009-12-18 2013-05-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ β細胞複製促進化合物およびそれらの使用法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
JP4896518B2 (ja) 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
AU2003297460A1 (en) 2002-12-19 2004-07-14 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
EP1644365A2 (en) 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20090196912A1 (en) 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
DK1789044T3 (da) 2004-09-06 2010-12-06 Basilea Pharmaceutica Ag Phenylaminopyridiner og phenylaminopyraziner
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
BRPI0807961A2 (pt) 2007-02-13 2017-05-16 Pharmacopeia Llc agonista de alfa2c adrenorreceptor funcionalmente seletivos.
GB0705566D0 (en) 2007-03-23 2007-05-02 Univ Dundee Method of treating learning impairment in down's syndrome subjects
EP2178537A4 (en) 2007-07-19 2011-08-17 Merck Sharp & Dohme BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
US20100173931A1 (en) * 2009-01-06 2010-07-08 Osteogenex Inc. Harmine derivatives for reducing body weight
WO2010123583A2 (en) 2009-04-24 2010-10-28 University Of Tennessee Research Foundation 1-aryl or 1-heteroaryl-pyrido[b]indoles and uses thereof
AU2010247412A1 (en) 2009-05-15 2011-11-24 Novartis Ag 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1
WO2010135589A2 (en) 2009-05-20 2010-11-25 Sakura Properties, Llc Dietary supplement drink for delivery of resveratrol and other polyphenols
JP2011006408A (ja) 2009-05-29 2011-01-13 Sumitomo Chemical Co Ltd 神経栄養因子の活性が関与する疾患の治療または予防剤
CN102791134B (zh) 2009-12-04 2015-04-22 魄金莱默有限公司 用多巴胺再摄取抑制剂及类似物治疗糖尿病症状和延迟或预防糖尿病相关病理学病况的方法
US20130102627A1 (en) 2010-04-09 2013-04-25 The Brigham And Women's Hospital, Inc. Acridines As Inhibitors Of Haspin And DYRK Kinases
WO2011133795A2 (en) 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
US9168247B2 (en) 2010-06-25 2015-10-27 Facultes Universitaires Notre Dame De La Paix Beta carboline derivatives useful in the treatment of proliferative disorders
AU2011290123B2 (en) 2010-08-09 2016-11-10 Takeda Pharmaceutical Company Limited Method of producing pancreatic hormone-producing cells
US20130165474A1 (en) 2010-08-17 2013-06-27 Travis Dunckley Compounds that inhibit tau phosphorylation
KR102006749B1 (ko) 2011-08-19 2019-08-02 디악쏘니 Dyrk1 억제제 및 이의 용도
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN103070862A (zh) 2011-10-25 2013-05-01 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物在制备抗菌药物中的应用
WO2013119518A1 (en) 2012-02-06 2013-08-15 The Regents Of The University Of California Small molecules for islet expansion
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
JP2016500080A (ja) 2012-11-26 2016-01-07 新疆華世丹薬物研究有限責任公司 ビスβ−カルボリン系化合物、その製造方法、医薬組成物および用途
JPWO2014058080A1 (ja) 2012-11-30 2016-09-05 国立研究開発法人理化学研究所 体細胞のリプログラミングを亢進させる方法、及び細胞作製キット
CN102977096B (zh) 2012-12-07 2014-12-17 中国药科大学 具有靶向特性的去氢骆驼蓬碱衍生物的抗肿瘤前药
MX2015007097A (es) 2012-12-10 2015-09-29 Hoffmann La Roche Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
US20150174034A1 (en) 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
SI2968284T1 (sl) 2013-03-14 2021-08-31 Osteoqc Inc. Alkil-amin harmin derivati za pospeševanje rasti kosti
WO2014151682A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
CN105555785B (zh) 2013-06-18 2019-03-01 4Sc股份公司 作为dyrk激酶抑制剂的2,3-二氢苯并呋喃-5-基化合物
GB2519623A (en) 2013-06-18 2015-04-29 4Sc Discovery Gmbh Method of inhibiting DYRK1B
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
ES2529865B8 (es) 2013-07-25 2016-01-22 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS
SI3057959T1 (en) 2013-10-17 2018-07-31 Vertex Pharmaceuticals Incorporated DNA-PK INHIBITORS
JP6767875B2 (ja) 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ, インコーポレイテッド Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法
US20170280720A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016064676A1 (en) 2014-10-21 2016-04-28 Genzada Pharmaceuticals Llc Human therapeutic agents
ES2985135T3 (es) 2014-12-18 2024-11-04 Harvard College Procedimientos para generar células ß derivadas de células madre y usos de las mismas
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
US11332716B2 (en) 2015-07-27 2022-05-17 The Regents Of The University Of California Methods and compositions for producing pancreatic beta cells
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN105884767B (zh) 2015-11-24 2018-01-19 西华大学 9‑位取代的吡啶并[3,4‑b]吲哚衍生物及其制备方法和作为SIRT蛋白抑制剂的用途
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US10487087B2 (en) 2015-12-30 2019-11-26 Vanderbilt University Positive allosteric modulators of the GLP-1 receptor
WO2017168245A1 (en) 2016-04-01 2017-10-05 University Of Limerick Pharmaceutical compositions and methods for the treatment of diabetes
WO2017197151A1 (en) 2016-05-11 2017-11-16 Emory University Phosphotidylinositol 3-kinase inhibitors
WO2018081401A1 (en) 2016-10-26 2018-05-03 Ichan School Of Medicine At Mount Sinai Method for increasing cell proliferation in pancreatic beta cells, treatmen t method.and composition
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
US11279703B2 (en) 2016-12-01 2022-03-22 Aptose Biosciences Inc. Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3124353A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US20230234935A1 (en) 2020-06-26 2023-07-27 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013514781A (ja) * 2009-12-18 2013-05-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ β細胞複製促進化合物およびそれらの使用法

Also Published As

Publication number Publication date
AU2019205944A1 (en) 2020-07-09
US12630803B2 (en) 2026-05-19
CA3086925A1 (en) 2019-07-11
US20210032601A1 (en) 2021-02-04
US20240174983A1 (en) 2024-05-30
EP3735419A4 (en) 2021-09-15
US11788064B2 (en) 2023-10-17
CN111819193A (zh) 2020-10-23
WO2019136320A1 (en) 2019-07-11
EP3735419A1 (en) 2020-11-11

Similar Documents

Publication Publication Date Title
US12630803B2 (en) Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
US20150297573A1 (en) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
US20120010178A1 (en) Methods and compounds for treatment of neurodegenerative disorders
AU2017281406A1 (en) Improved differentiation method
US10941384B2 (en) Compositions and methods for promoting the generation of endocrine cells
EP3813852B1 (en) Methods to induce terminal differentiation in stem cells by interfering with dna replication, methods of inducing pancreatic differentiation, and differentiated cells obtained thereof
CA3039220A1 (en) Method for increasing cell proliferation in pancreatic beta cells, treatment method, and composition
US20120053119A1 (en) Therapeutic method for increasing pancreatic beta cell mass
US20250186556A1 (en) Combination therapy with immunomodulators, dyrk1a inhibitors, and glp1r agonists for type 1 diabetes treatment
US20220088010A1 (en) Co-Administration of inhibitors to produce insulin producing gut cells
HK40041181A (en) Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
US20150051212A1 (en) Compositions And Methods For Inhibiting Drusen
US20240115564A1 (en) Htr1f antagonists for improvement of beta cell survival and function
Bauer The Impact of Mig6 on Pancreatic Endocrine Cell Fate: Alpha and Beta Cell Mass in Health and Disease
US20210324057A1 (en) Methods and compositions for treating and preventing t cell-driven diseases
Saraswati et al. Phosphodiesterases in the pathophysiology of diabetes mellitus
Ciancio et al. A RANDOMIZED LONG-TERM TRIAL OF TACROLIMUS/SIROLIMUS VERSUS TACROLIMUS/MYCOPHENOLATE VERSUS CYCLOSPORINE (NEORAL®)/SIROLIMUS IN RENAL TRANSPLANTATION: THREE YEAR ANALYSIS.
Saudek et al. ANTI-THYMOCYTE GLOBULIN PRESERVES RESIDUAL C-PEPTIDE PRODUCTION UN TYPE-1 DIABETES OF RECENT ONSET.
Eberhard The Essential Role of the Crtc2-CREB Pathway in β cell Function and Survival

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200904

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230727